Whitfield Dianne C.
SEC CIK 1839516 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| TARS | Tarsus Pharmaceuticals, Inc. | CHRO | 39.2K | — | $3.36M | 17 | 2022-11-29 | 2026-03-17 |
Most active insiders at TARS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Azamian Bobak R. | Pres, CEO, Board COB, Dir | — | $5.18M |
| 2 | LINK WILLIAM J PHD | Dir | — | $4.48M |
| 3 | Whitfield Dianne C. | CHRO | — | $2.69M |
| 4 | Lin Elizabeth Yeu | Chief Medical Off | — | $2.36M |
| 5 | Neervannan Seshadri | COO | — | $2.00M |
| 6 | Farrow Jeffrey S | See Remarks | — | $1.32M |
| 7 | Mottiwala Aziz | Chief Commercial Off | — | $892.5K |
| 8 | Wahl Bryan | GC | — | $850.4K |
| 9 | Goodrich Katherine | Dir | — | $183.4K |
| 10 | Goldberg Andrew D. | Dir | — | — |
Transactions 17
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-03-19 | 2026-03-17+ | TARS | Tarsus Pharmaceuticals, Inc. | Whitfield Dianne C. | CHRO | S - Sale | $68.36 | -12.3K | 39.2K | -24% | -$839.1K |
| D | 2026-03-17 | 2026-03-15 | TARS | Tarsus Pharmaceuticals, Inc. | Whitfield Dianne C. | CHRO | M - OptEx | — | +23.9K | 47.3K | +102% | — |
| M | 2026-01-06 | 2026-01-02 | TARS | Tarsus Pharmaceuticals, Inc. | Whitfield Dianne C. | CHRO | S - Sale | $80.67 | -15.6K | 33.2K | -32% | -$1.26M |
| 2025-12-18 | 2025-12-16 | TARS | Tarsus Pharmaceuticals, Inc. | Whitfield Dianne C. | CHRO | S - Sale | $80.10 | -7,397 | 39.0K | -16% | -$592.5K | |
| M | 2025-03-20 | 2025-03-18+ | TARS | Tarsus Pharmaceuticals, Inc. | Whitfield Dianne C. | CHRO | S - Sale | $47.88 | -6,711 | 46.4K | -13% | -$321.3K |
| D | 2025-03-18 | 2025-03-15 | TARS | Tarsus Pharmaceuticals, Inc. | Whitfield Dianne C. | CHRO | M - OptEx | — | +18.9K | 53.1K | +55% | — |
| D | 2024-03-19 | 2024-03-18 | TARS | Tarsus Pharmaceuticals, Inc. | Whitfield Dianne C. | CHRO | S - Sale+OE | $30.60 | -4,314 | 34.2K | -11% | -$132.0K |
| D | 2024-03-19 | 2024-03-15 | TARS | Tarsus Pharmaceuticals, Inc. | Whitfield Dianne C. | CHRO | M - OptEx | — | +11.7K | 38.5K | +44% | — |
| D | 2023-12-01 | 2023-11-30 | TARS | Tarsus Pharmaceuticals, Inc. | Whitfield Dianne C. | CHRO | S - Sale+OE | $16.31 | -8,355 | 26.8K | -24% | -$136.3K |
| D | 2023-12-01 | 2023-11-29 | TARS | Tarsus Pharmaceuticals, Inc. | Whitfield Dianne C. | CHRO | M - OptEx | $0.00 | +23.9K | 35.1K | +213% | $0 |
| M | 2023-03-23 | 2023-03-21+ | TARS | Tarsus Pharmaceuticals, Inc. | Whitfield Dianne C. | CHRO | S - Sale | $12.55 | -1,004 | 11.6K | -8% | -$12.6K |
| M | 2023-03-21 | 2023-03-17+ | TARS | Tarsus Pharmaceuticals, Inc. | Whitfield Dianne C. | CHRO | S - Sale | $12.94 | -649 | 12.6K | -5% | -$8,396 |
| D | 2023-03-17 | 2023-03-16 | TARS | Tarsus Pharmaceuticals, Inc. | Whitfield Dianne C. | CHRO | S - Sale+OE | $13.43 | -313 | 12.9K | -2% | -$4,204 |
| D | 2023-03-17 | 2023-03-15 | TARS | Tarsus Pharmaceuticals, Inc. | Whitfield Dianne C. | CHRO | M - OptEx | — | +4,462 | 13.2K | +51% | — |
| 2022-12-06 | 2022-12-02 | TARS | Tarsus Pharmaceuticals, Inc. | Whitfield Dianne C. | CHRO | S - Sale | $16.90 | -1,154 | 8,723 | -12% | -$19.5K | |
| DM | 2022-12-01 | 2022-11-30+ | TARS | Tarsus Pharmaceuticals, Inc. | Whitfield Dianne C. | CHRO | S - Sale+OE | $16.62 | -2,347 | 9,877 | -19% | -$39.0K |
| D | 2022-12-01 | 2022-11-29 | TARS | Tarsus Pharmaceuticals, Inc. | Whitfield Dianne C. | CHRO | M - OptEx | $0.00 | +10.3K | 12.2K | +520% | $0 |
Purchase Sale Sale after option exercise All abbreviations